The Department of Defense offers the NFRP Clinical Trial Award to support research aimed at significantly impacting the treatment or management of Neurofibromatosis. Projects can include evaluating new products, pharmacologic agents, devices, clinical guidance, and technologies through various types of clinical trials. From small proof-of-concept trials to large-scale efficacy studies, this grant provides funding for innovative approaches to advance the understanding and treatment of Neurofibromatosis. Application deadline is on August 09, 2018.
Opportunity ID: 305044
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-18-NFRP-CTA |
| Funding Opportunity Title: | DoD Neurofibromatosis Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 14, 2018 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 09, 2018 |
| Current Closing Date for Applications: | Aug 09, 2018 |
| Archive Date: | Sep 08, 2018 |
| Estimated Total Program Funding: | $15,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
The NFRP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept (i.e., pilot, first-in-human, or Phase 0) trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 305044 Full Announcement-FY18 NFRP CTA -> NFRP_FY18_CTA_IND_Documentation Form_GG.PDF
Folder 305044 Full Announcement-FY18 NFRP CTA -> NFRP_FY18_CTA PA_GG.PDF
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00242066 | May 14, 2018 | Aug 09, 2018 | View |
Package 1
Mandatory forms
305044 RR_SF424_2_0-2.0.pdf
305044 AttachmentForm_1_2-1.2.pdf
305044 RR_PersonalData_1_2-1.2.pdf
305044 RR_KeyPersonExpanded_2_0-2.0.pdf
305044 RR_Budget_1_4-1.4.pdf
305044 PerformanceSite_2_0-2.0.pdf
Optional forms
305044 RR_SubawardBudget30_1_4-1.4.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
